SK Biopharmaceuticals, SK Chemicals deal

The companies partnered to co-develop SK Biopharmaceuticals' YKP10811 to treat irritable bowel syndrome with constipation (IBS-C). SK Chemicals will have development and marketing rights in Korea, wh...